Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NPS Turns Attention To Teduglutide After Preos “Approvable” Letter

This article was originally published in The Pink Sheet Daily

Executive Summary

NPS says it will not continue development of Preos without a partner if FDA requests additional clinical trials.

You may also be interested in...



NPS Downsizes, Seeks Partners To Develop Preos And Teduglutide

Firm will reduce its workforce to 35 and focus on outsourcing and partnering to bring the two Phase III compounds to market.

NPS Downsizes, Seeks Partners To Develop Preos And Teduglutide

Firm will reduce its workforce to 35 and focus on outsourcing and partnering to bring the two Phase III compounds to market.

Preos “Approvable” Pending Additional Clinical Data, NPS Says

FDA concerns regarding hypercalcemia and Preos’ injection device call for additional safety information for the osteoporosis therapy.

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel